Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | GOT1 | P17174 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21805651 | 0.91 | EGFR (0.58) | EGFRERBB2CNR1MAPTGOT1 | |
| SCHEMBL29128711 | 0.84 | GAA (0.58) | EGFRERBB2MAPTGAASMN1; SMN2 | |
| SCHEMBL30797219 | 0.83 | MEN1 (0.69) | EGFRERBB2MAPTSMN1; SMN2EPHX1 | |
| SCHEMBL6687855 | 0.83 | MEN1 (0.69) | EGFRERBB2MAPTSMN1; SMN2EPHX1 | |
| SCHEMBL6688583 | 0.83 | MARS1 (0.60) | EGFRERBB2CNR1MAPTSMN1; SMN2 | |
| SCHEMBL6690983 | 0.81 | MAPT (0.50) | EGFRERBB2MAPTSMN1; SMN2GRIK1 | |
| SCHEMBL6690864 | 0.81 | MAPT (0.75) | MAPTSMN1; SMN2EPHX1KMT2ALMNA | |
| SCHEMBL3781565 | 0.81 | ALDH1A1 (0.67) | EGFRERBB2CNR1MAPTSMN1; SMN2 | |
| SCHEMBL5054174 | 0.81 | MARS1 (0.61) | CNR1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19707566 | 0.81 | GAA (0.65) | MAPTGAATGM2GRIK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| EP-3852752-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2021-07-28 | — | — | EP | disclosed |
| CN-113015526-A | Spirocyclic 2, 3-dihydro-7-azaindole compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| WO-2020061377-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061377-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2004106292-A1 | HALOETHYL UREA COMPOUNDS AND THEIR USE TO ATTENUATE, INHIBIT OR PREVENT NON-CANCEROUS PATHOGENIC CELLULAR PROLIFERATION AND DISEASES ASSOCIATED THEREWITH | IMOTEP INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004106291-A1 | HALOETHYL UREA COMPOUNDS AND THE USE THEREOF TO ATTENUATE, INHIBIT OR PREVENT CANCER CELL MIGRATION | IMOTEP INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | HIPK1, NEK1, HIPK2 | EGFR 4781/4885ERBB2 3176/4885CNR1 3392/4885 |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | HIPK1, NEK1, HIPK2 | EGFR 4781/4885ERBB2 3176/4885CNR1 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.